• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

553.48 +7.95 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? ↗
November 21, 2023
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
News headline image
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗
November 17, 2023
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
News headline image
The 3 Most Undervalued Biotech Stocks to Buy: November 2023 ↗
November 14, 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
News headline image
Analyst Ratings for Madrigal Pharmaceuticals ↗
November 13, 2023
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
November 02, 2023
 
Via Benzinga
News headline image
2 Risky Stocks With Massive Potential ↗
October 17, 2023
Neither is doing well this year. 
Via The Motley Fool
News headline image
1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street ↗
September 20, 2023
This company is on the brink of a major breakthrough. 
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading
September 13, 2023
Via Investor Brand Network
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
October 19, 2023
 
Via Benzinga
News headline image
Nike, Carnival And 3 Stocks To Watch Heading Into Friday ↗
September 29, 2023
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today? ↗
September 28, 2023
U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. 
Via Benzinga
Topics Stocks
News headline image
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. ↗
September 27, 2023
It has a good shot at commercializing a drug to treat a common liver disease. 
Via The Motley Fool
News headline image
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease ↗
September 21, 2023
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
News headline image
The Latest Analyst Ratings for Madrigal Pharmaceuticals ↗
September 11, 2023
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Marching Higher Today ↗
May 24, 2023
Two key tailwinds appear to be lifting the stock today. 
Via The Motley Fool
News headline image
Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line ↗
September 13, 2023
The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures. 
Via Investor's Business Daily
News headline image
Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday ↗
September 11, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to... 
Via Benzinga
Topics Stocks
News headline image
The 3 Best Biotech Stocks to Buy Now: September 2023 ↗
September 04, 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
News headline image
3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of ↗
August 30, 2023
Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months. 
Via InvestorPlace
News headline image
The 3 Most Promising Pharma Stocks to Own Now ↗
August 30, 2023
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
News headline image
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? ↗
August 23, 2023
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
News headline image
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It ↗
August 23, 2023
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
News headline image
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy? ↗
August 02, 2023
Novo Nordisk received some good news in a recent physician survey. 
Via The Motley Fool
News headline image
Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market ↗
June 30, 2023
Madrigal is working on gaining FDA approval for what could be the first NASH treatment. 
Via Investor's Business Daily
News headline image
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says ↗
June 28, 2023
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
June 27, 2023
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
News headline image
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street ↗
May 30, 2023
Recent moves to the upside could be the beginning of a much larger bull run. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
May 26, 2023
 
Via Benzinga
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Making Surprising Moves in Tuesday Session
May 23, 2023
Via Investor Brand Network
News headline image
Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug ↗
May 22, 2023
The FDA's advisors voted resoundingly against accelerated approval for obeticholic acid. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap